Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jasper Therapeutics

2.45
-0.2800-10.26%
Post-market: 2.520.0697+2.84%19:49 EDT
Volume:591.52K
Turnover:1.51M
Market Cap:36.80M
PE:-0.47
High:2.84
Open:2.75
Low:2.45
Close:2.73
52wk High:26.05
52wk Low:2.27
Shares:15.02M
Float Shares:9.14M
Volume Ratio:2.48
T/O Rate:6.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.2498
EPS(LYR):-4.8865
ROE:-101.34%
ROA:-56.50%
PB:0.87
PE(LYR):-0.50

Loading ...

Jasper Therapeutics Shares Plunge Premarket as Briquilimab Issues Upend Studies

Dow Jones
·
Jul 07

Jasper Therapeutics to stop ETESIAN study due to drug product lot issue

TIPRANKS
·
Jul 07

Jasper Therapeutics reports updated data from BEACON study

TIPRANKS
·
Jul 07

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

GlobeNewswire
·
Jul 07

Jasper Therapeutics Inc. Convened Annual Stockholders Meeting

Reuters
·
Jul 04

Jasper Therapeutics Unveils Presentation on KIT Inhibition and Briquilimab's Potential in Mast Cell Driven Diseases

Reuters
·
Jun 24

BTIG Sticks to Its Buy Rating for Jasper Therapeutics (JSPR)

TIPRANKS
·
Jun 21

Promising Efficacy and Safety in Jasper Therapeutics’ SPOTLIGHT Trial Supports Buy Rating

TIPRANKS
·
Jun 17

Jasper Therapeutics Shares Rise on Positive Data From Recent Study

Dow Jones
·
Jun 16

William Blair Remains a Buy on Jasper Therapeutics (JSPR)

TIPRANKS
·
Jun 16

Jasper Therapeutics presents data from SPOTLIGHT Phase 1b/2a study

TIPRANKS
·
Jun 16

Jasper Therapeutics Unveils New Insights on Briquilimab's Efficacy in Mast Cell Mediated Diseases

Reuters
·
May 21

Jasper Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
May 14

RBC Adjusts Price Target on Jasper Therapeutics to $46 From $48, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
May 13

Jasper Therapeutics Faces Financial Challenges Amid Rising R&D Costs

TIPRANKS
·
May 13

Jasper Therapeutics reports Q1 EPS ($1.41), consensus ($1.48)

TIPRANKS
·
May 13

Jasper Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Jasper Therapeutics Q1 EPS $(1.41) Misses $(1.33) Estimate

Benzinga
·
May 13

Jasper Therapeutics Inc expected to post a loss of $1.31 a share - Earnings Preview

Reuters
·
May 09

BRIEF-Jasper Therapeutics Inc Files For Common Stock Offering Of Up To $100 Million - SEC Filing

Reuters
·
Mar 27